Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years

Frontiers in Pharmacology

Monika Wojciechowska¹  Janusz Jaroszyński²  Anna Staniszewska³  Aneta Mela³  Maciej Niewada³  Bartłomiej Drop⁴  Anna Czajka⁵  Łukasz A. Poniatowski⁶  Beata Jagielska⁷  Jan Dąbrowski⁸  Marzena Furtak-Niczyporuk⁹  Witold Wrona^1,10 

[1] 0Department of Pediatric Nephrology, Medical University of Lublin, Lublin, Poland;Chair of Administrative Procedure, Faculty of Law and Administration, Maria Curie-Skłodowska University of Lublin, Lublin, Poland;Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland;Department of Information Technology and Medical Statistics, Faculty of Health Sciences, Medical University of Lublin, Lublin, Poland;Department of Neurology, Czerniakowski Hospital, Warsaw, Poland;Department of Neurosurgery, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland;Department of Oncological Diagnostics, Cardiooncology and Palliative Medicine, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland;Department of Pharmacology, National Medicines Institute, Warsaw, Poland;Department of Public Health, Faculty of Medicine, Medical University of Lublin, Lublin, Poland;HealthQuest Sp. z o.o., Warsaw, Poland;

关键词: drug programmes;    public payer expenditures;    reimbursement;    cancer drugs;    drug therapy;    hospital medicinal products;   

DOI  :  10.3389/fphar.2020.01123

来源: DOAJ

【 摘 要 】

BackgroundIn Poland drug programmes developed by the Minister of Health and financed by the National Health Fund are special reimbursement frameworks of innovative, expensive, and mostly hospital based medical products used for a small number of patients.Research DesignThe research presented in this paper is based on data analysis published by the National Health Fund in Poland. The analysis focused on estimating public payer expenditure on drugs available within drug programmes from 2015 to 2018.ResultsIn subsequent years, reimbursement of drugs used within drug programmes was associated with the National Health Fund budget expenditure of 635 mln USD, 755 mln USD, 854 mln USD, and 921 mln USD, respectively. Reimbursement of oncology drug programmes constituted 48.1%, 42.5%, 47.1%, and 52.4% and were approximately 305, 312, 402, 483 mln USD, whereas values of non-oncology drug programmes were approximately 330, 434, 452, and 438 mln USD which constituted 51.9%, 57.5%, 52.9%, and 47.6% respectively.ConclusionDespite the fact that the expenditure on drug programs in Poland are increasing every year, they undoubtedly improve the patient’s access to the most innovative oncological and nononcological therapies in the Polish healthcare system.

【 授权许可】

Unknown